HRP20181462T1 - Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva - Google Patents

Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva

Info

Publication number
HRP20181462T1
HRP20181462T1 HRP20181462TT HRP20181462T HRP20181462T1 HR P20181462 T1 HRP20181462 T1 HR P20181462T1 HR P20181462T T HRP20181462T T HR P20181462TT HR P20181462 T HRP20181462 T HR P20181462T HR P20181462 T1 HRP20181462 T1 HR P20181462T1
Authority
HR
Croatia
Prior art keywords
regorafenib
treatment
combination
colon cancer
acetylsalicylic acid
Prior art date
Application number
HRP20181462TT
Other languages
English (en)
Croatian (hr)
Inventor
Olaf Weber
Karl Ziegelbauer
Original Assignee
Bayer Pharma Aktiengesellschaft
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20181462(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma Aktiengesellschaft, Bayer Ag filed Critical Bayer Pharma Aktiengesellschaft
Publication of HRP20181462T1 publication Critical patent/HRP20181462T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20181462TT 2012-09-25 2013-09-23 Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva HRP20181462T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12185852 2012-09-25
EP13770659.4A EP2900269B1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating colorectal cancer
PCT/EP2013/069735 WO2014048881A1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer

Publications (1)

Publication Number Publication Date
HRP20181462T1 true HRP20181462T1 (hr) 2018-11-02

Family

ID=46963566

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181462TT HRP20181462T1 (hr) 2012-09-25 2013-09-23 Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva

Country Status (29)

Country Link
US (1) US10898500B2 (https=)
EP (1) EP2900269B1 (https=)
JP (1) JP6294888B2 (https=)
KR (1) KR102210575B1 (https=)
CN (1) CN104994876A (https=)
AU (1) AU2013322854B2 (https=)
BR (1) BR112015006686B1 (https=)
CA (1) CA2885688C (https=)
CL (1) CL2015000744A1 (https=)
CY (1) CY1120939T1 (https=)
DK (1) DK2900269T3 (https=)
EA (1) EA032023B1 (https=)
ES (1) ES2687985T3 (https=)
HK (1) HK1214169A1 (https=)
HR (1) HRP20181462T1 (https=)
HU (1) HUE039878T2 (https=)
IL (1) IL237690B (https=)
LT (1) LT2900269T (https=)
MX (1) MX357035B (https=)
MY (1) MY183969A (https=)
NZ (1) NZ705860A (https=)
PH (1) PH12015500587A1 (https=)
PL (1) PL2900269T3 (https=)
PT (1) PT2900269T (https=)
RS (1) RS57875B1 (https=)
SG (2) SG11201501963RA (https=)
SI (1) SI2900269T1 (https=)
WO (1) WO2014048881A1 (https=)
ZA (1) ZA201502840B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
MX368615B (es) 2012-09-25 2019-10-09 Hoffmann La Roche Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos.
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
DK3074400T3 (en) 2013-11-26 2018-01-15 Hoffmann La Roche Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors
EA032357B1 (ru) 2014-03-26 2019-05-31 Ф. Хоффманн-Ля Рош Аг Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
CA2937616A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
CN104829523B (zh) * 2014-04-30 2017-10-31 药源药物化学(上海)有限公司 瑞戈非尼盐及其晶型、制备方法
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
WO2017050732A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
JP6876685B2 (ja) 2015-09-24 2021-05-26 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Atx阻害剤としての二環式化合物
BR112017026682A2 (pt) 2015-09-24 2018-08-14 Hoffmann La Roche novos compostos bicíclicos como inibidores de dupla ação de atx/ca
AU2016328436B2 (en) 2015-09-24 2020-05-14 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
PL3474858T3 (pl) * 2016-06-28 2022-01-17 Asamedic As Dwuskładnikowa kompozycja zawierająca kwas acetylosalicylowy
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ.ホフマン-ラ ロシュ アーゲー Atxインヒビターとしての新規二環式化合物
CA3244313A1 (en) 2017-06-02 2025-06-13 Bayer Healthcare Llc Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
EP3501522A1 (en) 2017-12-22 2019-06-26 Asamedic AS Compositions comprising acetylsalicylic acid and a phosphate salt
EP3501523A1 (en) 2017-12-22 2019-06-26 Asamedic AS Two-component compositions comprising acetyl salicylic acid and a carbonate salt
KR20210156389A (ko) 2020-06-17 2021-12-27 재단법인대구경북과학기술원 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2373940A1 (en) * 1999-07-02 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Medicinal compositions for treating colorectal cancer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
EP1663978B1 (en) * 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
EP1948144A2 (en) * 2005-11-10 2008-07-30 Bayer HealthCare AG Diaryl urea for treating diabetic neuropathy
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
GB201002530D0 (en) * 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida

Also Published As

Publication number Publication date
BR112015006686B1 (pt) 2022-04-05
DK2900269T3 (en) 2018-10-01
EP2900269B1 (en) 2018-08-01
PH12015500587A1 (en) 2015-05-11
BR112015006686A2 (pt) 2019-08-27
IL237690A0 (en) 2015-05-31
CY1120939T1 (el) 2019-12-11
JP6294888B2 (ja) 2018-03-14
PT2900269T (pt) 2018-10-22
CA2885688C (en) 2021-03-02
SG11201501963RA (en) 2015-04-29
ES2687985T3 (es) 2018-10-30
SI2900269T1 (sl) 2018-10-30
RS57875B1 (sr) 2018-12-31
CL2015000744A1 (es) 2016-01-08
US10898500B2 (en) 2021-01-26
KR102210575B1 (ko) 2021-02-02
MY183969A (en) 2021-03-17
EA201500365A1 (ru) 2015-08-31
NZ705860A (en) 2018-07-27
MX357035B (es) 2018-06-25
AU2013322854B2 (en) 2018-07-19
HUE039878T2 (hu) 2019-02-28
AU2013322854A1 (en) 2015-04-02
IL237690B (en) 2019-07-31
CN104994876A (zh) 2015-10-21
EA032023B1 (ru) 2019-03-29
HK1214169A1 (zh) 2016-07-22
PL2900269T3 (pl) 2019-02-28
ZA201502840B (en) 2017-11-29
KR20150060869A (ko) 2015-06-03
WO2014048881A1 (en) 2014-04-03
JP2015529234A (ja) 2015-10-05
CA2885688A1 (en) 2014-04-03
US20150202214A1 (en) 2015-07-23
SG10201702356VA (en) 2017-04-27
EP2900269A1 (en) 2015-08-05
LT2900269T (lt) 2018-11-12
MX2015003728A (es) 2015-09-23

Similar Documents

Publication Publication Date Title
HRP20181462T1 (hr) Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva
IL289300A (en) Combination therapy for treating cancer
PT2919796T (pt) Utilização de akkermansia para o tratamento de distúrbios metabólicos
IL225471B (en) Compositions for the prevention and treatment of cancer
PL3296319T3 (pl) Sposoby leczenia nowotworu jelita grubego
HUE048876T2 (hu) Rákos megbetegedések kezelése
IL239007B (en) Eribulin for use in the treatment of breast cancer
PL2739153T3 (pl) Leczenie raka sutka
HUE036583T2 (hu) Notch jelzõ folyamat inhibitorai és alkalmazásuk rákok kezelésében
PT2768493T (pt) Fitocanabinoides para utilização no tratamento do cancro da mama
HUE043171T2 (hu) Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
HUE046667T2 (hu) Rák kombinatív kezelése
IL251083B (en) Compounds and compositions for the treatment of cancer
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
HRP20190046T1 (hr) Kombinirana terapija za liječenje raka
IL238177A0 (en) Methods and preparations for the treatment of cancer
EP3967315C0 (en) AKKERMANSIA MUCINIPHILA FOR THE TREATMENT OF CANCER
EP2830633A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
PL2914261T3 (pl) Śmiertelność syntetyczna i leczenie nowotworu
LT2914254T (lt) Kombinacinės terapijos chemoresistencinių vėžių gydymui
DK3434276T3 (da) Fremgangsmåde og farmaceutisk sammensætning til anvendelse i behandlingen af kræft
HUE045445T2 (hu) Kombinált terápia petefészekrák kezelésére
PL2742356T3 (pl) Środki prognostyczne w leczeniu nowotworów
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
LT2872176T (lt) Karboranilporfirinai, skirti naudoti vėžio gydymui